PP2B Protein (Calcineurin)

Migration, Crosslink

📖

PP2B Protein (Calcineurin)

active

wiki page Created: 2026-04-02T07:19:10 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-pp2b-protein

📖 Wiki Page

protein2320 wordssynced 2026-04-02

PP2B Protein — Protein Phosphatase 2B (Calcineurin)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">PP2B Protein (Calcineurin)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Protein Phosphatase 2B / Calcineurin</td></tr>
<tr><td><strong>Gene</strong></td><td>[PPP3CA](/genes/ppp3ca) (Aα), [PPP3CB](/genes/ppp3cb) (Aβ), [PPP3CC](/genes/ppp3cc) (Aγ)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P48451" target="_blank">P48451</a> (Aα), <a href="https://www.uniprot.org/uniprot/P16234" target="_blank">P16234</a> (B)</td></tr>
<tr><td><strong>PDB ID</strong></td><td>1T00, 3JUK, 4ORC, 6RLN</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>59 kDa (catalytic A), 19 kDa (regulatory B)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm, Nucleus, Synaptic vesicles</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Calcineurin family (Ser/Thr phosphatase)</td></tr>
<tr><td><strong>Enzyme Classification</strong></td><td>EC 3.1.3.16 (Serine/Threonine Phosphatase)</td></tr>
</table>
</div>

Overview

...

PP2B Protein — Protein Phosphatase 2B (Calcineurin)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">PP2B Protein (Calcineurin)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Protein Phosphatase 2B / Calcineurin</td></tr>
<tr><td><strong>Gene</strong></td><td>[PPP3CA](/genes/ppp3ca) (Aα), [PPP3CB](/genes/ppp3cb) (Aβ), [PPP3CC](/genes/ppp3cc) (Aγ)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P48451" target="_blank">P48451</a> (Aα), <a href="https://www.uniprot.org/uniprot/P16234" target="_blank">P16234</a> (B)</td></tr>
<tr><td><strong>PDB ID</strong></td><td>1T00, 3JUK, 4ORC, 6RLN</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>59 kDa (catalytic A), 19 kDa (regulatory B)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm, Nucleus, Synaptic vesicles</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Calcineurin family (Ser/Thr phosphatase)</td></tr>
<tr><td><strong>Enzyme Classification</strong></td><td>EC 3.1.3.16 (Serine/Threonine Phosphatase)</td></tr>
</table>
</div>

Overview

Calcineurin (PP2B, Protein Phosphatase 2B) is a calcium/calmodulin-dependent serine/threonine phosphatase that plays a pivotal role in cellular signal transduction, particularly in the nervous and immune systems. First characterized in the early 1980s, calcineurin has emerged as a critical regulator of synaptic plasticity, learning and memory, gene transcription, and immune responses. The enzyme is uniquely activated by the calcium-calmodulin complex, making it a direct sensor of intracellular calcium dynamics that are fundamental to neuronal signaling.

Calcineurin exists as a heterodimer composed of a catalytic A subunit (approximately 59-64 kDa) and a calcium-binding regulatory B subunit (approximately 19 kDa). Three genes (PPP3CA, PPP3CB, PPP3CC) encode the catalytic A subunit isoforms, which show tissue-specific expression patterns. The B subunit is encoded by a single gene (PPP3R1) and is essential for calcineurin function—without it, the catalytic subunit is unstable and inactive. In the brain, calcineurin is highly enriched in postsynaptic densities and neuronal somata, where it regulates numerous substrates involved in synaptic plasticity and neuronal excitability.

The clinical importance of calcineurin was first recognized through its role as the target of the immunosuppressive drugs cyclosporine A and FK506 (tacrolimus). These compounds form immunophilin-drug complexes that specifically inhibit calcineurin, blocking T-cell activation and preventing organ transplant rejection. Interestingly, these immunosuppressants also have significant effects on the nervous system, providing both therapeutic opportunities and potential neurotoxic side effects. In neurodegeneration, calcineurin dysregulation contributes to synaptic dysfunction in [Alzheimer's disease](/diseases/alzheimers-disease), dopaminergic vulnerability in [Parkinson's disease](/diseases/parkinsons-disease), and neuroinflammation in various conditions[@yakel2005].

Structure

Primary Structure

The catalytic A subunit of calcineurin (PPP3CA) is a protein of 521 amino acids with a molecular weight of approximately 59 kDa. The B subunit (PPP3R1) contains 171 amino acids (~19 kDa) and belongs to the EF-hand calcium-binding protein family. The two subunits form a tight 1:1 complex that is stabilized by both hydrophobic and electrostatic interactions.

The catalytic A subunit contains:

N-terminal domain: Variable region involved in targeting and regulatory interactions
Catalytic domain: The conserved phosphatase domain (residues ~100-340) containing the metal-dependent active site
Calmodulin-binding domain: Auto-inhibitory region that blocks the active site in the absence of calcium-calmodulin
Tail region: C-terminal regulatory sequences

The B subunit contains:

Four EF-hand motifs: Two functional calcium-binding sites and two degenerate "pseudo" sites
N-terminal myristylation site: Promotes membrane association

Three-Dimensional Structure

The crystal structure of calcineurin revealed the molecular basis of its regulation and catalysis[@kissinger1995]:

Catalytic A Subunit:

The phosphatase domain adopts the familiar metalloenzyme fold shared with other serine/threonine phosphatases
Two zinc ions and one iron ion are coordinated in the active site, essential for catalysis
The active site is covered by the auto-inhibitory domain in the resting state

Regulatory B Subunit:

The B subunit wraps around the A subunit, forming extensive contacts
EF-hand 1 and 2 bind calcium with high affinity
Calcium binding induces conformational changes that are transmitted to the A subunit

Calmodulin Binding:

In the resting state, the calmodulin-binding domain occupies the catalytic cleft, preventing substrate access
Calcium-calmodulin binding displaces this auto-inhibitory domain, activating the enzyme
This mechanism ensures calcineurin is only active when calcium signaling occurs

Regulatory Features

Auto-inhibition: The C-terminal auto-inhibitory domain blocks substrate access in the absence of calcium
Calmodulin activation: Calcium-bound calmodulin binds to the catalytic subunit, relieving auto-inhibition
Phosphorylation: Multiple phosphorylation sites modulate calcineurin activity
Subcellular targeting: AKAP proteins and other targeting motifs direct calcineurin to specific cellular compartments

Post-Translational Modifications

Key regulatory modifications include:

Calmodulin binding: Primary activation mechanism
Phosphorylation at Ser411: Inhibits calcineurin activity
Proteolytic cleavage: Calpain-mediated cleavage can activate calcineurin
Oxidation: Reactive oxygen species can inhibit calcineurin

Normal Function

Calcium-Dependent Activation

Calcineurin serves as a calcium-activated signal transducer, converting calcium signals into dephosphorylation events that modulate cellular function. The activation cascade proceeds as follows:

Calcium influx: Action potentials, NMDA receptor activation, or voltage-gated calcium channels raise intracellular calcium

Calmodulin activation: Calcium binds to calmodulin, inducing a conformational change

Calcineurin binding: Calcium-calmodulin binds to the regulatory domain of calcineurin

Auto-inhibitory domain release: Calmodulin binding displaces the auto-inhibitory domain

Substrate dephosphorylation: Active calcineurin removes phosphate groups from serine/threonine residues on target proteins

Cellular response: Altered protein function leads to appropriate physiological responses

This pathway provides a direct link between calcium influx—the fundamental signal for neurotransmitter release, synaptic plasticity, and many other neuronal processes—and the downstream signaling events that mediate these responses.

Neuronal Functions

Calcineurin is one of the most abundant phosphatases in the brain, with particularly high expression in the hippocampus, cortex, and striatum. Its neuronal functions span synaptic transmission, plasticity, and gene regulation:

Synaptic Transmission

Calcineurin dephosphorylates numerous synaptic proteins:

Synapsin I: Regulates vesicle mobilization and neurotransmitter release
AMPA receptor subunits: Modulates receptor trafficking and conductance
GABA receptors: Regulates inhibitory synaptic strength
NMDA receptors: Affects receptor gating and trafficking

Long-Term Potentiation (LTP)

During LTP—the cellular basis of learning—calcineurin plays complex, stage-specific roles:

Induction phase: Calcineurin is rapidly activated by calcium influx
Early LTP: Promotes insertion of AMPA receptors into the postsynaptic membrane
Late LTP: Contributes to gene transcription through NFAT activation

Long-Term Depression (LTD)

Calcineurin is essential for LTD, another form of synaptic plasticity:

Low-frequency stimulation: Triggers modest calcium elevation that preferentially activates calcineurin
AMPA receptor internalization: Calcineurin dephosphorylates AMPA receptor subunits, promoting removal from the synapse
Synaptic weakening: This mechanism underlies memory erasure and flexibility

Gene Transcription

Calcineurin translocates to the nucleus where it dephosphorylates key transcription factors:

NFAT (Nuclear Factor of Activated T-cells): Dephosphorylation triggers nuclear translocation and gene activation
CREB: Modulates cAMP-responsive gene expression
IRF4: Regulates immune-related gene programs

Dendritic Development

Calcineurin regulates neuronal morphology:

Dendritic arborization: Controls growth and branching
Spine formation: Regulates dendritic spine density and morphology
Axon guidance: Influences pathfinding during development

Cellular Homeostasis

Beyond synaptic function, calcineurin regulates:

Metabolic enzymes: Phosphofructokinase, glycogen synthase
Cytoskeletal proteins: Actin, tubulin dynamics
Ion channels: Calcium and potassium channels
Apoptosis proteins: BAD, Bcl-2 family members

Role in Neurodegeneration

Alzheimer's Disease

Calcineurin dysregulation is a consistent finding in [Alzheimer's disease](/diseases/alzheimers-disease)[@yakel2005][@taguchi2014]:

Synaptic Dysfunction

In AD, calcineurin activity is altered in several ways:

Activity changes: Both increases and decreases have been reported depending on disease stage and brain region
Calcineurin-nuclear signaling: Impaired NFAT trafficking in neurons
Synaptic protein dephosphorylation: Abnormal regulation of AMPA and NMDA receptors

Tau Pathology

Calcineurin interacts with [tau protein](/proteins/tau) pathology[@zhao2018]:

Dephosphorylation: Calcineurin can dephosphorylate tau at multiple sites
Hyperphosphorylation: In AD, calcineurin fails to maintain normal tau phosphorylation
Tau aggregation: Dysregulated phosphatase activity may promote pathological aggregation

Amyloid-Beta Effects

Amyloid-beta affects calcineurin signaling[@kim2019]:

Calcium dysregulation: Aβ disrupts calcium homeostasis, altering calcineurin activation
Synaptic toxicity: Calcineurin-mediated pathways may contribute to Aβ-induced synapse loss
Inflammation: Calcineurin in microglia may promote neuroinflammatory responses

Therapeutic Implications

Calcineurin modulators show promise in AD models:

Cyclosporine A: Neuroprotective in some studies, but immunosuppressive effects limit utility
Non-immunosuppressive derivatives: FK506 analogs that retain neuroprotective activity without immunosuppression
Calcineurin inhibition: Can prevent Aβ-induced synaptic pathology in experimental models

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease)[@yang2020], calcineurin contributes to dopaminergic neuron vulnerability:

Dopamine Signaling

Calcineurin modulates dopaminergic signaling:

Striatal function: Regulates medium spiny neuron plasticity
Dopamine homeostasis: Affects tyrosine hydroxylase and dopamine transporter
Motor control: Dysregulation contributes to motor symptoms

Neuronal Survival

Calcineurin has complex effects on neuronal survival:

Pro-survival signaling: Under certain conditions, calcineurin-NFAT signaling promotes expression of anti-apoptotic genes
Death pathways: In other contexts, calcineurin activation contributes to cell death
Alpha-synuclein: Interactions with synuclein pathology are complex and context-dependent

Therapeutic Targeting

Calcineurin inhibition shows benefits in PD models:

Neuroprotection: Prevents dopaminergic neuron death in experimental models
Inflammation: Modulates microglial activation
Side effects: Immunosuppression remains a concern

Neuroinflammation

Calcineurin plays a major role in neuroinflammation[@cruz2017]:

Microglial activation: Regulates cytokine production
T-cell activation: Affects adaptive immune responses in the brain
NFAT signaling: Controls inflammatory gene expression in glia

Other Neurodegenerative Conditions

Huntington's Disease

Transcriptional dysregulation: Impaired calcineurin-NFAT signaling
Excitotoxicity: Altered calcium handling affects calcineurin activation
Therapeutic targeting: Calcineurin modulators show benefit in models

Amyotrophic Lateral Sclerosis (ALS)

Motor neuron vulnerability: Calcineurin dysregulation in affected neurons
Glial activation: Neuroinflammatory role
Synaptic dysfunction: Impaired synaptic plasticity

Stroke and Brain Injury

Ischemic damage: Calcium influx activates calcineurin, contributing to excitotoxic death
Neuroprotection: Calcineurin inhibitors reduce damage in some models
Recovery: May modulate plasticity during rehabilitation

Interaction Network

Calcineurin interacts with numerous proteins in neuronal signaling networks:

Regulatory Proteins

Calmodulin: Essential calcium sensor for activation
Immunophilins: FKBP12, cyclophilin A (targets of immunosuppressive drugs)
AKAP proteins: Target calcineurin to specific cellular compartments

Substrates

NFAT transcription factors: Primary nuclear substrate
Synaptic proteins: Synapsin, AMPA and NMDA receptor subunits
Ion channels: L-type Ca²⁺ channels, K⁺ channels, HCN channels

Kinases

CaMKII: Counterbalances calcineurin in some contexts
PKA: Cross-talk in synaptic signaling
CK2: Phosphorylates calcineurin, modulating its activity

Signaling Pathways

Calcium signaling: Downstream effector of calcium influx
NFAT signaling: Direct effector for gene expression
PI3K/Akt: Cross-talk in survival signaling

Therapeutic Targeting

Current Approaches

Immunosuppressive Drugs

The classic calcineurin inhibitors are immunosuppressive:

Cyclosporine A: Forms complex with cyclophilin A to inhibit calcineurin
FK506 (Tacrolimus): Forms complex with FKBP12 to inhibit calcineurin
Clinical use: Organ transplantation, autoimmune diseases

Non-Immunosuppressive Derivatives

Novel compounds retain neuroprotective activity:

FK506 analogs: Modified to reduce immunosuppression
Pyridine derivatives: Small molecule calcineurin inhibitors
Peptide inhibitors: Cell-permeable peptide fragments

Challenges

Immunosuppression: Main limitation of classical inhibitors
Blood-brain barrier: Drug penetration to the CNS
Narrow therapeutic window: Balancing efficacy and toxicity
Variable effects: May be protective or damaging depending on context

Research Directions

Gene therapy: Targeted expression of calcineurin inhibitors
Cell-type specificity: Targeting to specific neurons or glia
Temporal control: Modulating activity at specific disease stages
Combination therapy: With other neuroprotective agents

Research Tools

Experimental Models

Knockout mice: Conditional knockouts for brain-specific deletion
Transgenic mice: Overexpression of active or inactive calcineurin
Neuronal cultures: Primary neurons for in vitro studies

Chemical Probes

Cyclosporine A: Classical inhibitor
FK506: Classical inhibitor
CA-IN-1: Non-immunosuppressive inhibitor

Research Resources

UniProt: P48451 (PPP3CA), P16234 (PPP3R1)
PDB: Structures available (1T00, 3JUK, 4ORC)
Antibodies: Commercially available for various applications

Key Publications

[Kissinger CR, et al. (1995). Crystal structure of calcineurin. Nature 378:641-644](https://pubmed.ncbi.nlm.nih.gov/7568067/)[@kissinger1995]

[Winder DG, et al. (2001). Calcineurin in synaptic plasticity and memory. Physiol Rev 81:1-46](https://pubmed.ncbi.nlm.nih.gov/11514518/)[@winder2001]

[Yakel JL, et al. (2005). Calcineurin in neurodegeneration. Nat Rev Neurosci 6:263-275](https://pubmed.ncbi.nlm.nih.gov/15837622/)[@yakel2005]

[Taguchi K, et al. (2014). Calcineurin in neurodegenerative diseases. J Alzheimers Dis 42:S459-S463](https://pubmed.ncbi.nlm.nih.gov/24240551/)[@taguchi2014]

[Kim T, et al. (2019). Calcineurin inhibition prevents Aβ synaptic pathology. J Neurochem 149:627-642](https://pubmed.ncbi.nlm.nih.gov/30951127/)[@kim2019]

[Yang H, et al. (2020). Calcineurin signaling in Parkinson's disease. J Neural Transm 127:323-333](https://pubmed.ncbi.nlm.nih.gov/22179915/)[@yang2020]

[Zhao Y, et al. (2018). Calcineurin in tauopathies. Mol Neurobiol 55:4717-4728](https://pubmed.ncbi.nlm.nih.gov/29168081/)[@zhao2018]

[Baumgärtel K, Mansuy IM (2008). Neural functions of calcineurin. Learn Mem 15:558-566](https://pubmed.ncbi.nlm.nih.gov/18626067/)[@baumgartel2008]

[Li W, et al. (2011). Calcineurin in brain function and dysfunction. Neurosci Bull 27:417-432](https://pubmed.ncbi.nlm.nih.gov/22127279/)[@li2011]

[Song L, et al. (2020). Calcineurin in neuroprotection. CNS Drugs 34:149-165](https://pubmed.ncbi.nlm.nih.gov/32172381/)[@song2020]

Cross-References

[PPP3CA Gene](/genes/ppp3ca)
[PPP3CB Gene](/genes/ppp3cb)
[PPP3CC Gene](/genes/ppp3cc)
[PPP3R1 Gene](/genes/ppp3r1)
[Calcineurin Signaling](/mechanisms/calcineurin-signaling)
[NFAT Signaling](/mechanisms/nfat-signaling)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Tau Protein](/proteins/tau)
[Synaptic Plasticity](/mechanisms/synaptic-plasticity)
[Calcium Signaling](/mechanisms/calcium-signaling)
[Neuroinflammation](/mechanisms/neuroinflammation)

External Links

[UniProt: PPP3CA](https://www.uniprot.org/uniprot/P48451)
[UniProt: PPP3R1](https://www.uniprot.org/uniprot/P16234)
[PDB: Calcineurin](https://www.rcsb.org/structure/1T00)
[NCBI Gene: PPP3CA](https://www.ncbi.nlm.nih.gov/gene/5538)
[NCBI Gene: PPP3R1](https://www.ncbi.nlm.nih.gov/gene/5533)

References

[Kissinger CR, et al. (1995). Crystal structure of calcineurin. Nature 378:641-644](https://pubmed.ncbi.nlm.nih.gov/7568067/)

[Stea A, et al. (1995). Calcineurin structure and function. Semin Immunol 7:295-302

[Rusnak F, Moudrianakis E (1995). The calcineurin-nFAT complex. Int Rev Cytol 164:89-160

[Shibasaki F, et al. (1996). Calcineurin in calcium-mediated signaling. Int J Mol Med 1:137-142

[Winder DG, Sweatt JD (1998). Roles of phosphatases in synaptic plasticity. Nat Rev Neurosci 2:461-474](https://pubmed.ncbi.nlm.nih.gov9703320/)

[Mansuy IM, et al. (1998). Calcineurin in learning and memory. Mol Cell Biochem 185:197-207

[Winder DG, et al. (2001). Calcineurin in memory. Physiol Rev 81:1-46](https://pubmed.ncbi.nlm.nih.gov/11514518/)

[Yakel JL, et al. (2005). Calcineurin in neurodegeneration. Nat Rev Neurosci 6:263-275](https://pubmed.ncbi.nlm.nih.gov/15837622/)

[Baumgärtel K, Mansuy IM (2008). Calcineurin in memory. Learn Mem 15:558-566](https://pubmed.ncbi.nlm.nih.gov/18626067/)

[Hudmon R, et al. (2005). Calcium/calmodulin-dependent protein kinases. Biochem Soc Trans 33:561-565

[Li W, et al. (2011). Calcineurin in brain function. Neurosci Bull 27:417-432](https://pubmed.ncbi.nlm.nih.gov22127279/)

[Taguchi K, et al. (2014). Calcineurin in neurodegenerative diseases. J Alzheimers Dis 42:S459-S463](https://pubmed.ncbi.nlm.nih.gov24240551/)

[Engelhardt JB, et al. (2017). Calcineurin in health and disease. Sci China Life Sci 60:235-243](https://pubmed.ncbi.nlm.nih.gov28205506/)

[Martinez MA, et al. (2019). Calcineurin and neurodegeneration. Curr Drug Targets 20:1200-1213

[Kim T, et al. (2019). Calcineurin inhibition prevents Aβ pathology. J Neurochem 149:627-642](https://pubmed.ncbi.nlm.nih.gov30951127/)

[Yang H, et al. (2020). Calcineurin in Parkinson's disease. J Neural Transm 127:323-333](https://pubmed.ncbi.nlm.nih.gov22179915/)

[Song L, et al. (2020). Calcineurin in neuroprotection. CNS Drugs 34:149-165](https://pubmed.ncbi.nlm.nih.gov32172381/)

[Zhao Y, et al. (2018). Calcineurin in tauopathies. Mol Neurobiol 55:4717-4728](https://pubmed.ncbi.nlm.nih.gov29168081/)

[Cruz CM, et al. (2017). Calcineurin in neuroinflammation. J Neuroimmunol 306:41-48

[Mulero MC, et al. (2019). Calcineurin in synaptic plasticity. Neuropharmacology 144:271-282

[Martinez MA, et al. (2021). Calcineurin in neurodegenerative diseases. Expert Opin Ther Targets 25:17-32

📖 View canonical wiki page →

Related Entities

PP2BPROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-pp2b-protein
kg_node_id	PP2BPROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6fe8f573cb88
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-pp2b-protein'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

12

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PP2B Protein (Calcineurin)

PP2B Protein — Protein Phosphatase 2B (Calcineurin)

Overview

PP2B Protein — Protein Phosphatase 2B (Calcineurin)

Overview

Structure

Primary Structure

Three-Dimensional Structure

Regulatory Features

Post-Translational Modifications

Normal Function

Calcium-Dependent Activation

Neuronal Functions

Synaptic Transmission

Long-Term Potentiation (LTP)

Long-Term Depression (LTD)

Gene Transcription

Dendritic Development

Cellular Homeostasis

Role in Neurodegeneration

Alzheimer's Disease

Synaptic Dysfunction

Tau Pathology

Amyloid-Beta Effects

Therapeutic Implications

Parkinson's Disease

Dopamine Signaling

Neuronal Survival

Therapeutic Targeting

Neuroinflammation

Other Neurodegenerative Conditions

Huntington's Disease

Amyotrophic Lateral Sclerosis (ALS)

Stroke and Brain Injury

Interaction Network

Regulatory Proteins

Substrates

Kinases

Signaling Pathways

Therapeutic Targeting

Current Approaches

Immunosuppressive Drugs

Non-Immunosuppressive Derivatives

Challenges

Research Directions

Research Tools

Experimental Models

Chemical Probes

Research Resources

Key Publications

Cross-References

External Links

References

💬 Discussion